BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 01-Nov-2020

(Continuation news of BXPHARMA): The Bonus Share is declared out of accumulated profit. The Bonus Share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post-dividend retained earnings become negative. (end)

BXPHARMA 01-Nov-2020

Dividend Declaration (Additional Information): The Company has further informed that declared Bonus Share along with the Cash Dividend considering its requirements of cash for the ongoing expansion projects and the investment needed in connection with Covid-19 Vaccine for which an exclusive distribution agreement has been signed with Serum Institute of India Pvt. Ltd (SII). (cont.)

BXPHARMA 29-Oct-2020

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2019, unaudited financials up to March 31, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

BXPHARMA 29-Oct-2020

There will be no price limit on the trading of the shares of the Company on today (29.10.2020) for following its corporate declaration. however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.

BXPHARMA 29-Oct-2020

The Board of Directors has recommended 15% cash and 10% stock dividend for the year ended on June 30, 2020. Date of AGM: 19.12.2020, Time: 10:30 AM, Venue: Digital Platform. Record Date: 25.11.2020. The Company has also reported Consolidated EPS of Tk. 8.67, Consolidated NAV per share of Tk. 80.12 and Consolidated NOCFPS of Tk. 13.67 for the year ended on June 30, 2020 as against Tk. 7.48, Tk. 72.96 and Tk. 7.30 respectively for the same period of the previous year.

BXPHARMA 21-Oct-2020

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2020 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.

BXPHARMA 23-Jun-2020

(Q3 Un-audited): Consolidated EPS was Tk. 2.22 for January-March 2020 as against Tk. 1.84 for January-March 2019; Consolidated EPS was Tk. 6.48 for July 2019-March 2020 as against Tk. 5.51 for July 2018-March 2019. Consolidated NOCFPS was Tk. 9.83 for July 2019-March 2020 as against Tk. 6.48 for July 2018-March 2019. Consolidated NAV per share was Tk. 77.88 as on March 31, 2020 and Tk. 70.99 as on March 31, 2019.

BXPHARMA 17-Jun-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on June 22, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.

BXPHARMA 29-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 2.12 for October-December 2019 as against Tk. 1.81 for October-December 2018; Consolidated EPS was Tk. 4.26 for July-December 2019 as against Tk. 3.67 for July-December 2018. Consolidated NOCFPS was Tk. 9.14 for July-December 2019 as against Tk. 2.10 for July-December 2018. Consolidated NAV per share was Tk. 75.66 as on December 31, 2019 and Tk. 69.15 as on December 31, 2018.

BXPHARMA 21-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

Previous Next page